GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultimovacs ASA (OSL:ULTI) » Definitions » Cash Flow from Financing

Ultimovacs ASA (OSL:ULTI) Cash Flow from Financing : kr-1.85 Mil (TTM As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Ultimovacs ASA Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Dec. 2023, Ultimovacs ASA paid kr0.00 Mil more to buy back shares than it received from issuing new shares. It received kr0.00 Mil from issuing more debt. It paid kr0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received kr0.00 Mil from paying cash dividends to shareholders. It received kr0.22 Mil on other financial activities. In all, Ultimovacs ASA earned kr0.22 Mil on financial activities for the three months ended in Dec. 2023.


Ultimovacs ASA Cash Flow from Financing Historical Data

The historical data trend for Ultimovacs ASA's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultimovacs ASA Cash Flow from Financing Chart

Ultimovacs ASA Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only 343.00 151.02 259.96 3.58 -1.85

Ultimovacs ASA Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.60 -0.54 -0.54 -0.54 -0.24

Ultimovacs ASA Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Ultimovacs ASA's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

Ultimovacs ASA's Cash from Financing for the quarter that ended in Dec. 2023 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-1.85 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ultimovacs ASA  (OSL:ULTI) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Ultimovacs ASA's issuance of stock for the three months ended in Dec. 2023 was kr0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Ultimovacs ASA's repurchase of stock for the three months ended in Dec. 2023 was kr0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Ultimovacs ASA's net issuance of debt for the three months ended in Dec. 2023 was kr0.00 Mil. Ultimovacs ASA received kr0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Ultimovacs ASA's net issuance of preferred for the three months ended in Dec. 2023 was kr0.00 Mil. Ultimovacs ASA paid kr0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Ultimovacs ASA's cash flow for dividends for the three months ended in Dec. 2023 was kr0.00 Mil. Ultimovacs ASA received kr0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Ultimovacs ASA's other financing for the three months ended in Dec. 2023 was kr0.22 Mil. Ultimovacs ASA received kr0.22 Mil on other financial activities.


Ultimovacs ASA Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Ultimovacs ASA's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Ultimovacs ASA (OSL:ULTI) Business Description

Traded in Other Exchanges
Address
Ullernchausseen 64, Oslo, NOR, 0379
Ultimovacs ASA is a pharmaceutical company involved in developing novel immunotherapies against cancer. Its product candidate is UV1, a peptide-based vaccine inducing T cell responses against the universal cancer antigen telomerase. The company and its proprietary technology are based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital.